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Background: Mutations in RMRP, encoding a non-coding RNA molecule, underlie
cartilage-hair hypoplasia (CHH), a syndromic immunodeficiency with multiple
pathogenetic mechanisms and variable phenotype. Allergy and asthma have been
reported in the CHH population and some patients suffer from autoimmune (AI)
diseases.
Objective: We explored AI and allergic manifestations in a large cohort of Finnish
patients with CHH and correlated clinical features with laboratory parameters and
autoantibodies.
Methods: We collected clinical and laboratory data from patient interviews and
hospital records. Serum samples were tested for a range of autoantibodies including
celiac, anti-cytokine, and anti-21-hydroxylase antibodies. Nasal cytology samples were
analyzed with microscopy.
Results: The study cohort included 104 patients with genetically confirmed
CHH; their median age was 39.2 years (range 0.6–73.6). Clinical autoimmunity
was common (11/104, 10.6%) and included conditions previously undescribed in
subjects with CHH (narcolepsy, psoriasis, idiopathic thrombocytopenic purpura, and
multifocal motor axonal neuropathy). Patients with autoimmunity more often had
recurrent pneumonia, sepsis, high immunoglobulin (Ig) E and/or undetectable IgA
levels. The mortality rates were higher in subjects with AI diseases (χ2(2) = 14.056,
p = 0.0002). Several patients demonstrated serum autoantibody positivity without
compatible symptoms. We confirmed the high prevalence of asthma (23%) and
allergic rhinoconjunctivitis (39%). Gastrointestinal complaints, mostly persistent diarrhea,
were also frequently reported (32/104, 31%). Despite the history of allergic
rhinitis, no eosinophils were observed in nasal cytology in five tested patients.
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Conclusions: AI diseases are common in Finnish patients with CHH and are associated
with higher mortality, recurrent pneumonia, sepsis, high IgE and/or undetectable IgA
levels. Serum positivity for some autoantibodies was not associated with clinical
autoimmunity. The high prevalence of persistent diarrhea, asthma, and symptoms of
inflammation of nasal mucosa may indicate common pathways of immune dysregulation.
Keywords: allergy, asthma, autoantibodies, enteropathy, RMRP
INTRODUCTION
Cartilage-hair hypoplasia (CHH, OMIM #250250) is caused by
mutations in RMRP, which encodes the long non-coding RNA
component of mitochondrial RNA-processing endoribonuclease.
CHH is characterized by metaphyseal chondrodysplasia,
hair hypoplasia, combined immunodeficiency, anemia, and
increased risk of malignancies. Autoimmune (AI) diseases
have occasionally been reported in CHH, such as enteropathy,
hemolytic anemia (AIHA), hypoparathyroidism, hypo- or
hyperthyroidism, juvenile rheumatoid arthritis and neutropenia
(1–4). The prevalence of asthma is increased and has been
reported in 16% (4/25) of Amish and 24% (10/34) of Finnish
patients (3, 5). Allergic rhinoconjunctivitis is also excessively
prevalent (41%, 23/56) in the Finnish CHH population (6).
RMRP mutations induce cell cycle abnormalities resulting in
defective proliferation and increased apoptosis of T cells (7, 8).
Patients with CHH have markedly reduced numbers of recent
thymic emigrants and low naïve CD4+ and CD8+ cells, but
normal counts of CD4+CD25highCD127low regulatory T cells
and double-negative T cells (6, 8). Eosinophilia and increased
immunoglobulin (Ig) E levels are uncommon (6).
The knowledge of the disease mechanisms in CHH has
expanded in recent years to include impaired gene regulation
(9) and defects in telomere biology (10, 11). In addition, lack
of autoimmune regulator (AIRE) expression and absence
of Foxp3+ T cells in the thymus of a single patient with
CHH has been reported (12). The loss of AIRE function
associated with AIRE mutations is responsible for Autoimmune
Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy
(APECED), a recognized polyendocrine syndrome with defective
T and B cell tolerance (13, 14). This could support a possible
role of impaired regulatory T cell function in the pathogenesis of
CHH.
We have recently demonstrated broad autoantibody reactivity
in subjects with CHH using the microarray technique (15).
Compared with healthy controls, CHH patients showed
significantly higher reactivity for autoantibodies against gliadin,
nuclear antigens, thyroglobulin, vitronectin, as well as for
myositis-specific antibodies.
In order to further explore the prevalence and characteristics
of AI and allergic manifestations in individuals with CHH, we
Abbreviations: AI, autoimmune; AIHA, autoimmune hemolytic anemia;
APECED, Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal
Dystrophy; CHH, cartilage-hair hypoplasia; DVA, duodenal villous atrophy;
Ig, immunoglobulin; IL, interleukin; RMRP, RNA component of mitochondrial
RNA-processing endoribonuclease.
analyzed clinical and laboratory data for a large group of Finnish
CHH patients. We also tested serum samples from several of
these patients for a variety of autoantibodies. To complement our
previous research, we applied different measurement methods
and tested mostly for autoantibodies that were not included in
our recent study (15).
METHODS
We originally invited all known Finnish patients with CHH to
a prospective cohort study in 1985–1991. Those who agreed
to participate (Cohort 1, n = 80) underwent interview, clinical
examination and blood sampling; RMRP mutation testing was
performed when the gene was identified in 2001. A follow-
up visit was conducted in 2012–2015, when Cohort 1 and all
other thus far identified Finnish CHH patients were contacted
and invited for a clinical visit and blood tests. This study thus
included three groups of patients (in total 104 patients): (1)
patients fromCohort 1 who attended the follow-up visit (n= 32),
(2) patients from Cohort 1 who were unavailable for the follow-
up visit (n = 48), and (3) patients recruited to the study at
the follow-up visit (Cohort 2, n = 24). We collected complete
data by means of interviews and from hospital records for all
patients participating the follow-up visit (n = 56). For those
patients from Cohort 1 who did not attend the follow-up visit, we
obtained health information from two Finnish National Medical
Databases. The Care Register for Health Care has since 1969
recorded the activities of health centers, hospitals and other
institutions providing inpatient care, as well as home-nursing
care. Outpatient primary health care data was derived from the
Register of Primary Health Care Visits, which covers all health
centers in Finland since 2011. Database information included
health service providers, dates of the visits, diagnoses, as well
as diagnostic and therapeutic procedures. We then contacted
all identified hospitals and requested all patients’ detailed health
records for the analysis. Special attention was given to the signs
and symptoms attributed to autoimmunity, such as skin rashes,
joint symptoms and gastrointestinal complaints and they were
systematically discussed during the interviews.
Asthma diagnosis was made by physicians and/or
pulmonologists using spirometry and assessment of response
to asthma medications. Allergy was similarly diagnosed by
physicians based on clinical presentation and in some cases, on
skin tests and/or serum specific IgE levels. Sepsis diagnosis was
made by physicians and supported by positive findings in blood
cultures.
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Serum samples for autoantibody measurement were obtained
from those who agreed to donate blood at the follow-up
visit (n = 33) and stored at −70◦C until analyses. The
analyzed autoantibodies were related to celiac disease, based on
frequent gastrointestinal complaints among the patients, and on
autoantibodies that are commonly seen in patients with AIRE
mutations (Table 1). One of the eight chosen autoantibodies
(deamidated gliadin peptide IgG) has previously been tested with
microarray technique in 16 of the available 33 samples (15).
To further evaluate the cause for symptoms related to
rhinoconjuctivitis we examined nasal samples for eosinophilic,
neutrophilic and goblet cells from five patients with
physician-diagnosed allergic rhinitis. Subjects had refrained
from application of local nasal decongestants, steroids or
systemic antihistamines prior to sampling. Samples were
taken during spring and summer months (May–August),
from both anterior nares beneath the middle turbinates using
a standard cotton swab. Samples were let to set on a glass
slide at room temperature. Cytology was evaluated by an
experienced technician using eosin-methylene blue staining and
microscopy.
Statistical analyses were performed with IBM SPSS version
23 software. Fisher’s exact test, logistic regression analysis and
Kaplan-Meier method were implicated when appropriate.
The study protocol was approved by the Institutional Research
Ethics Committee at Helsinki University Hospital, Finland, and
informed consents were obtained from all participants and
caregivers.
RESULTS
Our study group included 104 patients (61 women, 43 men) with
genetically confirmed CHH. Their median age at the last follow-
up was 39.2 years (range 0.6–73.6 years). There were 17 children
aged <18.0 years, 49 young adults (18.0–45.0 years) and 38
adults aged >45.0 years. The majority of patients (n = 79; 76%)
were homozygous for the g.70A>G RMRPmutation, others were
compound heterozygous for g.70A>G and either g.262G>T
(n = 22; 21%) or duplication TACTCTGTGA at −13 (n = 3;
3%).
Altogether 11 patients (11/104, 10.6%) had been diagnosed
with AI conditions (Table 2). Clinical features of all study
patients are presented in Table 3. In addition to AI diseases
that have been previously reported in patients with CHH
(enteropathy, hemolytic anemia, hyperthyroidism, and
juvenile rheumatoid arthritis), we report psoriasis, idiopathic
thrombocytopenic purpura, narcolepsy, and multifocal
motor axonal neuropathy all of which have been regarded
as autoimmune diseases (19–22).
Among those with autoimmunity, recurrent pneumonia, and
sepsis were more frequently documented than in those without
autoimmunity (6/11, 55% vs. 13/93, 14%, p= 0.001, B coefficient
2.65 and 4/11, 36% vs. 6/93, 6%, p = 0.019, B coefficient 2.14,
respectively). Rates of autoimmunity were higher in patients with
elevated IgE levels (2/5, 40%; p = 0.011, B coefficient 2.96) and
in patients with undetectable IgA levels (3/5, 60%; p = 0.036, B
coefficient 3.33), as compared with patients with normal IgE and
IgA levels.
Among patients from Cohort 1, 10/80 individuals have
developed AI diseases during follow-up. The Kaplan-Meier
analysis (log rank test) of these 80 patients demonstrated that
survival distributions for patients with and without AI conditions
were significantly different, χ2
(2)
= 14.056, p= 0.0002 (Figure 1).
More than half of our patients (56/104, 54%) suffered from
arthralgia or morning joint stiffness, but only one was diagnosed
with genuine seronegative juvenile polyarthritis. Osteoarthritis
was common among patients with arthralgia (20/56, 36%) and
was increasingly prevalent with increasing age. Mean age at last
follow-up in those with osteoarthritis was 51.7 years, while it was
35.2 years in those without osteoarthritis. Patients with a history
of arthralgia reported more often sinusitis (38/56, 68% vs. 18/48,
38%, p = 0.002, B coefficient 1.3) and pollen allergy (27/56, 48%
vs. 13/48, 27%, p = 0.035, B coefficient 0.95). When arthralgia,
asthma and diarrhea were compiled in a Venn diagram (n= 71),
asthma and diarrhea overlapped with arthralgia in 7 and 12
patients, respectively (Figure 2). The overlap, however, did not
TABLE 1 | Antibody assays performed on serum samples of patients with cartilage-hair hypoplasia.
Antibody Abbreviation Measurement method Normal values in adults*
Deamidated gliadin peptide IgA DGP-IgA FEIA <7 U/ml
Deamidated gliadin peptide IgG DGP-IgG FEIA <7 U/ml
Tissue transglutaminase IgA tTG-IgA FEIA <7 U/ml
Tissue transglutaminase IgG tTG-IgG FEIA <10 U/ml
Endomysium IgA EMA-IgA IIF Titer <5
Endomysium IgG EMA-IgG IIF Titer <5
Interleukin 17 IgG IL-17 Radioligand binding1 <218 Index
Interleukin 22 IgG IL-22 Radioligand binding1 <270 Index
Interferon ω IgG IFN-ω Radioligand binding2 <200 Index
21-Hydroxylase IgG 21-OH Radioligand binding3 <57 Index
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TABLE 2 | Autoimmune conditions diagnosed in 11 out of 104 patients with cartilage-hair hypoplasia.
No. AI disease Age at diagnosis
of AI disease, yrs
Age at the latest
follow-up, yrs
Treatment Outcome of AI disease Other symptoms
1 Enteropathy 3 Died in young
adulthood




















4 Narcolepsy 11 Young adulthood None specific, narcolepsy
was not related to influenza
vaccine
No remission Allergy, anemia
5 AIHA 11 Died in
adolescence
Prednisolone Remission after short
course of therapy
Anemia, pneumonia, sepsis
Psoriasis 12 Local therapy Disease under control until
death
Enteropathy 14 None specific Died from pneumonia
following profound diarrhea
6 Graves’ disease 15 Young adulthood Carbimazole, thyroidectomy Cured after thyroidectomy Allergy, arthralgia






8 Celiac disease* 30 Died in adulthood Unknown Unknown. Died from
pneumonia
Arthralgia, pneumonia
9 Enteropathy 35 Young adulthood None specific Investigations ongoing Anemia, arthralgia,
pneumonia





11 Ulcerative colitis 68 Died in mature
adulthood
Mesalamine Disease under control until





AI, autoimmune; AIHA, autoimmune hemolytic anemia; HCQ, hydroxychloroquine; i/a, intra-articular; ITP, idiopathic thrombocytopenic purpura; IVIG, intravenous immunoglobulin;
MMAN, multifocal motor axonal neuropathy; MTX, methotrexate; No, patient number; NSAID, nonsteroidal anti-inflammatory drug; yrs, years. *data on histopathology is not available.
reach statistical significance. This group of 71 patients contained
most of the patients with AI conditions (10/11).
Gastrointestinal symptoms were common in our cohort
(32/104, 31%) and the most frequent complaint was
prolonged/recurrent diarrhea. In at least three patients with
diarrhea, broad screening for bacterial, viral and parasitic
infections was negative. Twelve patients followed lactose-free
diet, but this did not alleviate diarrhea. Eight patients had
undergone colonoscopy, with normal results in all except
one subject with ulcerative colitis. Gastroscopy findings were
abnormal in 10/18 patients and included gastroesophageal reflux
(n = 5), chronic gastritis (n = 5), peptic ulcer (n = 2), and/or
duodenal villous atrophy (DVA, n = 3). Another patient had
received the diagnosis of celiac disease, but data on histology
were unavailable. Significantly more patients with diarrhea
reported arthralgia (18/23, 78% vs. 38/81, 47%, p = 0.011, B
coefficient 1.41), as compared with those without diarrhea. In
the subgroup of patients with osteoarthritis (n = 20), diarrhea
was not more common than in those without osteoarthritis.
Anemia was diagnosed in 32 patients (31%), mostly in
childhood. Thirteen of these patients (41%) required red blood
cell transfusions. Two subjects had AIHA, in others anemia was
hypoplastic and attributed to CHH itself and mostly resolved by
adulthood. Four of the patients required blood transfusions as
adults. There were no cases of AI neutropenia, but one patient
had idiopathic thrombocytopenic purpura.
Physician-diagnosed asthma (23%) and allergy (39%) were
both highly prevalent. Asthma was diagnosed in 29% (5/17)
of children and in 22% (19/87) of adults. In some patients
with clinical symptoms of pollen allergy, skin testing and/or
serum allergen-specific IgE testing had been negative. Elevated
IgE levels were infrequently documented (5/69 patients), also
in subjects without allergic symptoms. Eosinophilia was more
common in subjects with pollen allergy (5/34, 15% vs. 1/50,
2%, p = 0.038). Hospitalization for pneumonia and/or surgery
for sinopulmonary and/or ear infections were more common in
patients with asthma [19/24 (79%) vs. 31/80 (39%), p = 0.019, B
coefficient 1.13].
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TABLE 3 | Clinical and laboratory characteristics of 104 patients with cartilage-hair hypoplasia.
Manifestations No. of patients (%) Comments
Recurrent sinopulmonary and/or ear infections
Hospitalization and/or surgery required
84/104 (81)
50/80 (63)
Acute otitis media, rhinosinusitis and/or pneumonia
Tympanostomy and/or sinus surgery
Physician-diagnosed asthma 24/104 (23)




Skin testing and/or allergen-specific serum IgE





















Normal results in eight (8/18, 44%) patients









Elevated IgE* 5/69 (7)
Elevated deamidated gliadin peptide IgA 2/33 (6) Values of 9 and 20 (normal <7 U/ml)
Elevated deamidated gliadin peptide IgG 2/33 (6) Values of 10 and 14 (normal <7 U/ml)
Elevated interferon ω IgG 1/33 (3) Value of 206 (normal <200 Index)
Elevated 21-Hydroxylase IgG 2/33 (6) Values of 67 and 77 (normal <57 Index)
AIHA, autoimmune hemolytic anemia; Ig, immunoglobulin; No, number. *According to local laboratory age-adjusted reference values.
Subgroup of Patients Tested for
Autoantibodies
Serum samples were available from 33 adult patients (21
women, 12 men) at median age of 45.4 years (range 19.9–69.1
years). One patient was receiving immunoglobulin substitution
at the time of blood sampling, he tested negative for all
autoantibodies. One had unmeasurable IgA, therefore EMA-
IgG and tTG-IgG were measured in serum with normal
results. In a few patients, we detected slightly elevated
autoantibodies including anti-interferon-ω IgG (IFN-ω,
n = 1), anti-21-hydroxylase IgG (21-OH, n = 2), anti-
gliadin-peptide IgA (n = 2) and anti-gliadin-peptide IgG
(n = 2; Tables 3, 4). These patients had no celiac disease and
none of the typical manifestations of APECED, including
adrenal insufficiency, hypoparathyroidism and mucocutaneous
candidiasis. All other autoantibodies tested negative in all
patients.
Subgroup of Patients Tested for Nasal
Cytology
Nasal samples were available from five patients. Although they all
reported physician-diagnosed allergic rhinitis, eosinophils were
almost absent in all subjects, only two out of five subjects had
single cells visible unilaterally (Table 5). Further, neutrophils
were detected in moderate amounts in only one patient, and
goblet cells in another. Lymphocytes were not found in any
samples.
DISCUSSION
We demonstrate high prevalence (11/104, 10.6%) of AI
conditions in a large cohort of Finnish patients with CHH
compared with the prevalence of 5.4% in general Finnish
population (23). Autoimmunity, allergy, diarrhea, arthralgia, and
asthma in our patients may reflect common pathways of immune
dysregulation behind these symptoms.
With microarray technique, multiple autoantibodies have
been demonstrated in all (n = 16) tested serum samples
from patients with CHH (15). The absence of compatible
symptoms may reflect the benign nature of these antibodies,
consistent with reported presence of autoantibodies in healthy
individuals (24). RMRP mutations may contribute to AI
phenomena by various mechanisms, such as impaired Th17
cell functions or altered expression of AIRE. Autoantibodies
typically observed in APECED patients (IFN-ω, IL-17, IL-
22, 21-OH) have not been included in our previous study.
Here, we describe positivity for these antibodies in three
of our patients, but the indices were close to the limit
of positivity and the patients had no compatible clinical
manifestations. Thus, the significance of these findings is
uncertain.
The data on the CD4+CD25highCD127low regulatory T cells
measured in 11 patients from our cohort has previously been
published (6). The numbers of regulatory T cells were normal
in 10/11 patients, including two patients with autoimmunity
(measured after the development of AIHA and juvenile
idiopathic arthritis) and low in a single 67-year-old patient
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FIGURE 2 | Modified Venn diagram of arthralgia, asthma, persistent diarrhea and their combinations in 71 patients with cartilage-hair hypoplasia. n, number of
patients. Stars indicate patients with autoimmune diseases.
without AI manifestations. However, functional abnormalities in
regulatory T cells cannot be excluded and the role of CTLA-4
deficiency behind the immune dysregulation should be further
explored.
Many of our study patients described gastrointestinal
problems, most commonly recurrent and/or prolonged diarrhea.
Eleven of our patients avoided lactose, which did not improve
diarrhea. Endoscopy was not systematically performed in
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TABLE 4 | Results of autoantibody measurements in 33 patients with cartilage-hair hypoplasia.



















1 – + – + + <7 <7 <7 <5 211 −52 34 23
2 – – – – – <7 14 <7 <5 −5 81 64 55
3 – + – + – 20 10 7 <5 −2 −9 62 −27
4 – + – + – <7 <7 <7 <5 64 2 −50 −34
5 – – – + – <7 <7 <7 <5 −49 −25 0 6
6 – + + – – 7 7 <7 <5 −37 30 13 40
7 – + + + – <7 <7 <7 <5 −30 −70 111 11
8 – + + + – <7 <7 <7 <5 31 101 155 35
9 – + + + – <7 <7 <7 <5 −28 −7 49 −33
10 – + + + + <7 <7 <7 <5 −53 84 49 47
11 – + + – – <7 <7 <7 <5 −62 23 −39 −21
12 – – + + + <7 <7 <7 <5 −40 90 136 67
13 – + – + + <7 <7 <7 <5 −84 −95 −48 −30
14 – + – + – <7 <7 <7 <5 −27 99 22 15
15 – – – – – <7 <7 <7 <5 −10 −60 171 46
16 – – – – – <7 <7 <7 <5 −32 39 29 11
17 – + – + – <7 <7 <7 <5 −32 73 48 77
18 – – + + – <7 <7 <7 <5 −62 −11 −46 7
19 – + – + + <7 <7 <7 <5 −52 −110 −110 −4
20 – + + – – 9 <7 <7 <5 −42 −27 −86 −21
21 – – – – – <7 <7 <7 <5 −26 15 −36 46
22 – + – – – <7 <7 <7 <5 16 105 130 77
23 – – + – – <7 <7 <7 <5 −59 50 79 54
24 – – – + – <7 <7 <7 <5 −66 3 54 16
25 – – – – – <7 <7 <7* <5* 51 37 68 18
26 – + – – – <7 <7 <7 <5 −38 −10 42 21
27 – – – – – <7 <7 <7 <5 48 183 −194 −4
28 – – – – – <7 <7 <7 <5 −98 −71 −71 −1
29 – + + – – <7 <7 <7 <5 −69 −18 −45 4
30 – – + + + <7 <7 <7 <5 −69 19 −202 −30
31 – – – – – <7 <7 <7 <5 −8 66 206 38
32 – – + + – <7 <7 <7 <5 −32 90 69 30
33 – + + + – <7 <7 <7 <5 −51 −17 40 40
Numbers in bold represent elevated values. For reference values please see Table 1. *Because of immunoglobulin A deficiency diagnosed in this patient, tTG-IgG and EMA-IgG were
measured, both were negative. 21-OH, 21-hydroxylase; AI, autoimmune disease; BA, bronchial asthma; DGP, deamidated gliadin peptide; EMA, endomysium; G/i, gastrointestinal
symptoms; IFN, interferon; Ig, immunoglobulin; IL, interleukin; No, number; Pt, patient; tTG, tissue transglutaminase.
patients with CHH and thus AI enteropathy cannot be excluded.
The presence of DVA in three subjects with negative celiac
screen underscores the necessity for systematic endoscopic
evaluation of CHH individuals with gastrointestinal complaints.
Apart from celiac disease, DVA is frequent in patients with
common variable immunodeficiency and numerous other
disorders, and DVA etiology should always be identified and
treated to prevent malnutrition and malignant transformation
(25, 26).
Serum tissue transglutaminase (tTG) IgA was negative in all
tested patients and tTG IgG was negative in a single patient
with IgA deficiency. However, in our previous microarray study
(15), five out of 16 patients tested positive for tTG IgG and two
of them reported diarrhea, therefore the possible link between
tTG antibodies and gastrointestinal symptoms in patients with
CHH deserves further studies. Isolated positive tTG IgG is
uncommon in celiac disease, but can be present in other AI
conditions, including inflammatory bowel disease (27). The
discordance of positivity for tTG IgG in our current and previous
study may be explained by higher sensitivity of microarray
technique.
Asthma was more common in individuals with CHH who
required hospitalization and/or surgery for sinopulmonary
and/or ear infections. This may suggest asthma as a marker
for a more severe immunodeficiency in CHH but may
also reflect the retrospective nature of our study and the
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TABLE 5 | Cytology of nasal cells from five subjects with cartilage-hair hypoplasia.
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5
Symptoms Pollen allergy,
rhinoconjuctivitis
Pollen allergy Pollen allergy, nasal congestion,





Nasal side Right Left Right Left Right Left Right Left Right Left
Lymphocytes – – – – – – – – – –
Eosinophils – (+) – – – – (+) – – –
Neutrophils – + – + – – (+) (+) ++ ++
Goblet cells ++ ++ (+) (+) – – – – (+) (+)
Grading of eosinophilic cells (per microscopic view): –, 0 cells; +/-, 1-3 cells; +, 3–5 cells; ++, 20–30 cells; + + +, cells predominate. Grading of neutrophilic cells (per microscopic
view): –, no cells; +, cells clearly visible; ++, moderate number of cells visible.
influence of age, with accumulation of infectious episodes and
asthma diagnoses in older patients. Asthma was not associated
with pollen allergy in this cohort, raising the question of
possible misdiagnosis of one or both of these disorders in
some patients. Asthma diagnosis is challenging in CHH due
to the absence of height-age-adjusted reference values for
spirometry.
Autoimmunity has been implied as a mechanism for
lung disease in some patients with APECED and asthma-
like symptoms, airway hyperresponsiveness and bronchiectasis
(28, 29). We have previously demonstrated high prevalence
of bronchiectasis in individuals with CHH, also in those
without clinical signs of immunodeficiency (5). Thus, some
patients with CHH designated to have asthma, may instead
suffer from an underlying autoimmune lung disease and
pulmonary problems in subjects with CHH require further
investigations.
Four of the eleven patients with AI diseases died of pneumonia
or end-stage lung disease. Although in three of them lung
manifestations preceded the onset of autoimmunity, we suggest
that patients with CHH and AI conditions should be carefully
evaluated for pulmonary symptoms and consideration given for
prophylactic antibiotics and/or immunoglobulin substitutions to
prevent lung damage from recurrent infections.
In allergic rhinitis and asthma, eosinophils are recruited
by pro-inflammatory cytokines and mediators and are the
predominant cells in later phases of an allergic response (30, 31).
The role of neutrophils in allergic inflammation is debated,
but some studies report increasing numbers in nasal cytology
in patients with allergic rhinitis (32–34). While all five tested
subjects reported recurrent or chronic symptoms of allergic
rhinitis and nasal samples were collected during the peak pollen
season, none had increased numbers of eosinophilic, neutrophilic
or lymphocytic nasal cells. This points to the presence of a
chronic mucous inflammation, congruent with the systemic
immune dysregulation, also supported by the fact that some
patients with symptoms of pollen allergy tested negative for
allergens.
In conclusion, we report here a high prevalence and
a wide spectrum of AI diseases in a large cohort of
patients with CHH. We report mild positivity for some
autoantibodies, not associated with clinical autoimmunity.
The high prevalence of arthralgia, persistent diarrhea,
asthma and symptoms of inflammation of nasal mucosa
may indicate common pathways of immune dysregulation.
Gastrointestinal, pulmonary and joint symptoms in subjects
with CHH should be thoroughly evaluated to exclude underlying
autoimmunity.
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